Life Science JumpStart
Often viewed as cost-prohibitive, Baker Tilly’s Oracle team has created, JumpStart, a new variant of our implementation methodology, revolutionizing the accessibility of Oracle to start-up level organizations.
Life Science JumpStart
Innovation is the lifeblood for the life sciences industry
This top disruptor is driving start-ups to develop connected digital health, diagnostics and data science applications at a rapid rate, all while executing trials, reviewing therapeutic learnings and maintaining compliance and regulatory requirements.
Digital transformation is being adopted for process transformation with the hopes of increasing efficiency. These investments can reduce risk, digitize paper-based or legacy systems and help usher in an increase in quality blending big data analytics and artificial intelligence (AI) with quality management. Improved digital connectivity can also create a more efficient transfer of technical knowledge from research and development (R&D) to manufacturing to speed up commercialization and reduce costs.
Protect and enhance your company’s value with JumpStart
Oracle is unique in offering a comprehensive cloud solution that is future ready. This digital foundation can also reduce complexities as the organization scales or plans for additional investment rounds. Oracle’s back-office technology has matured to provide end-to-end capabilities. This includes the ability to run the back-office functions in an efficient manner.
Baker Tilly created JumpStart within the Oracle cloud platform, revolutionizing the accessibility of Oracle cloud to organizations early in their maturity
Driven by Baker Tilly’s industry expertise and leading implementation experience, JumpStart is intended to expedite the implementation process while minimizing the effort and impact on your team.
With JumpStart, an organization can scale their back-office functionality to coincide with the often-drastic increase in need presented upon FDA approval.
Package options
Growth Focused Foundation
Using industry leading practices
- Chart of accounts
- Legal entities
- Organizational structures
SOX compliant general ledger and accounts payable
Efficient Procure-to-Pay foundation
Rolling cash flow projections
Clinical trial costing
Joint venture reporting
Core employee structures
Real time “out of box” financial analytics
Reduced risk and increased efficiencies
Ideal for organizations
- Establishing a foundation for future growth
- Desiring real-time analytics to make
data-driven decisions - Seeking real time visibility into cash flow projections and burn rates
- Spending too much time making manual entries and tracking Procure-to-Pay processes
- Desiring a streamlined approach to tracking drug development costs
- Seeking to reduce human errors and risk
Foundational Package Plus
- Drug portfolio management and prioritization
- Expand Procure-to-Pay process with automation, AI and vendor management
- Expense planning
- Trial inventory management
- Critical recruiting needs such as sales reps and trial patients
- Clinical trial data management
- FDA submission data management
Ideal for Organizations
- Realizing the probability of FDA submissions are higher after positive early phase results
- Increasing spending with vendors and clinical trials
- Seeking quicker and better analytics to make real time decisions
- Wanting to eliminate inefficient expense management processes
- Processing large amounts of POs to match to invoices that are consuming critical resources
- Needing to streamline clinical trial tracking with analytics aiding prioritizing decisions
- With typical clinical trials exceeding 500 patients or have more than a few therapies coming out of R&D efforts
Value Realization Package Plus
- Manufacturing execution
- Validated process manufacturing
- Transportation management for tracing in transit environmental inventory data
- Quality
- Order management/fulfillment
- Cash receipts and application
Ideal for organizations
- Planning to manufacture in-house or weighing in-house vs outsourced manufacturing decision
- Expecting FDA decision/approvals and commercialization within 12-18 months
